











Surfactant protein A as a biomarker of outcomes of anti-fibrotic 
























Resource Version Publisher Version 
 
brought to you by COREView metadata, citation and similar papers at core.ac.uk
RESEARCH ARTICLE Open Access
Surfactant protein A as a biomarker of
outcomes of anti-fibrotic drug therapy in
patients with idiopathic pulmonary fibrosis
Takumi Yoshikawa†, Mitsuo Otsuka* , Hirofumi Chiba†, Kimiyuki Ikeda, Yuki Mori, Yasuaki Umeda,
Hirotaka Nishikiori, Koji Kuronuma and Hiroki Takahashi
Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is a progressive and fibrosing lung disease with poor prognosis.
Pirfenidone and nintedanib are anti-fibrotic drugs used for patients with IPF. These drugs reduce the rate of decline
in forced vital capacity (FVC). Serum surfactant protein (SP)-A, SP-D, and Krebs von den Lungen-6 (KL-6) are
monitoring and prognostic biomarkers in patients with IPF; however, their relationship with the therapeutic
outcomes of anti-fibrotic drugs has not been investigated. We aim to clarify whether serum SP-A, SP-D, and KL-6
reflect therapeutic outcomes of pirfenidone and nintedanib administration in patients with IPF.
Methods: We retrospectively investigated patients with IPF who were initiated on pirfenidone or nintedanib
administration between January 2014 and June 2018 at our hospital. Changes in clinical parameters and serum SP-
A, SP-D, and KL-6 levels were evaluated. Patients with ≥10% decline in FVC or ≥ 15% decline in diffusing capacity of
the lung for carbon monoxide (DLco) from baseline to 6 months were classified as progression group, while the
other patients were classified as stable group.
Results: Forty-nine patients were included (pirfenidone, 23; nintedanib, 26). Stable group comprised 32 patients,
while progression group comprised 17 patients. In the stable group, changes in SP-A and KL-6 from baseline to 3
and 6 months significantly decreased compared with the progression group (SP-A: 3 months − 6.0% vs 16.7%, 6
months − 10.2% vs 20.2%, KL-6: 3 months − 9.2% vs 6.7%, 6 months − 15.0% vs 12.1%, p < 0.05). Changes in SP-A
and SP-D levels showed significant negative correlations with the change in %FVC (r = − 0.46 and r = − 0.39, p <
0.01, respectively) and %DLco (r = − 0.67 and r = − 0.54, p < 0.01, respectively). Similar results were also seen in
subgroup analysis for both pirfenidone and nintedanib groups. On logistic regression analysis, decrease in SP-A
from baseline to 3 months and 6 months was found to predict the outcomes at 6 months (odds ratios: 0.89 and
0.88, respectively).
Conclusions: Changes in serum SP-A reflected the outcomes of anti-fibrotic drug therapy. Serum SP-A has a
potential as a biomarker of therapeutic outcomes of anti-fibrotic drugs.
Keywords: Surfactant protein-A (SP-A), Surfactant protein-D (SP-D), Krebs von den Lungen-6 (KL-6), Idiopathic
pulmonary fibrosis (IPF), Pirfenidone, Nintedanib
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Background
Idiopathic pulmonary fibrosis (IPF) is a chronic, progres-
sive fibrosing interstitial lung disease of unknown eti-
ology [1]. Patients with IPF have a poor prognosis. The
clinical course is typically characterized by acute exacer-
bations, progression to respiratory failure, and a high
risk of lung cancer. The reported median survival of
these patients is 3–5 years [2, 3]. Lung transplantation is
the only curative treatment for IPF. However, notable
advances have recently been made in pharmacological
therapy (pirfenidone and nintedanib) for patients with
IPF [4, 5].
Pirfenidone and nintedanib were shown to exhibit both
anti-fibrotic and anti-inflammatory effects in patients with
IPF; these were shown to reduce the rate of decline in
forced vital capacity (FVC) and ameliorate disease pro-
gression [4, 5]. Pirfenidone has several anti-inflammatory
and anti-fibrotic effects, including inhibition of collagen
synthesis, down-regulation of transforming growth factor
beta (TGF-β), and reduction in fibroblast proliferation [6].
Nintedanib is an intracellular inhibitor of tyrosine kinase
that inhibits vascular endothelial growth factor (VEGF),
fibroblast growth factors (FGFs), and platelet-derived
growth factors (PDGFs) receptors [5]. Consequently, the
ATS/ERS/JRS/ALAT statement conditionally recom-
mends the use of pirfenidone and nintedanib in patients
with IPF [7].
Progression of IPF is monitored by respiratory symp-
toms, pulmonary function tests (PFTs), and high-
resolution computed tomography (HRCT) [8]. Of these
parameters, PFTs are the most important methods for
objective monitoring and quantification of disease pro-
gression. In particular, decline in FVC and diffusion cap-
acity of the lung for carbon monoxide (DLco) are
surrogate markers for clinical monitoring and prognostic
assessment of patients with IPF [9]. In ASCEND and
INPULSIS-1/2 trials, the primary endpoint was the an-
nual rate of decline in FVC [4, 5]. Amelioration of the
decline in FVC and DLco over time is the only indicator
for evaluation of therapeutic effect. Therefore, it is desir-
able to develop other biomarkers for assessment and
prediction of therapeutic efficacy.
Surfactant protein (SP)-A and SP-D are secretory pro-
teins that belong to the collectin family, while Krebs von
den Lungen (KL)-6 is a mucin-like high-molecular-
weight glycoprotein classified as MUC-1 mucin. These
are produced mainly by alveolar type II cells [10, 11].
These have been widely proved as serum biomarkers for
the diagnosis of interstitial lung disease [10–12]; in
addition, these were shown to be related to progression
of IPF and the associated mortality [12–14]. However,
the relationship between the changes in these serum bio-
markers and the effects of pirfenidone and nintedanib in
patients with IPF has not been reported. The purpose of
this study was to assess whether these serum biomarkers
reflect the changes in FVC and DLco, and could serve as
biomarkers to monitor the therapeutic outcomes of pir-
fenidone and nintedanib in patients with IPF.
Methods
Subjects
We performed a retrospective cohort study of consecu-
tive patients with IPF who were treated at Sapporo Med-
ical University Hospital. This study was approved by the
Institutional Review Board of Sapporo Medical Univer-
sity Hospital (#302–120, dated November 8, 2018). The
requirement for written informed consent of patients
was waived off because of the retrospective nature of the
study. IPF was diagnosed according to the ATS/ERS/
JRS/ALAT IPF statement 2018 [1]. Ninety-three patients
with IPF were newly initiated on pirfenidone or ninteda-
nib therapy between January 2014 and June 2018. We
included patients with IPF who were treated with pirfe-
nidone or nintedanib for ≥6 months. Pulmonary function
tests (PFTs) were conducted after 6 months of initiation
of treatment. We excluded patients with lung cancer,
serious cardiovascular disease, serious infection, or colla-
gen disease at the time of administration of pirfenidone
or nintedanib. Also, we excluded patients using cortico-
steroids, immunosuppressants, or N-acetylcysteine dur-
ing the observation period, because their therapies may
affect the serum levels of the biomarkers.
Pirfenidone and nintedanib treatment
The daily dose of pirfenidone was increased in a step-
wise manner from 600mg to 1200–1800mg every 2
weeks, as previously described [15]. The median max-
imum dose was 1500 mg (inter-quartile range [IQR],
1200–1800 mg), and the median final dose was 1200 mg
(IQR, 1200–1800 mg). Nintedanib was initiated at a daily
dose of 300 mg. The dose was decreased depending on
the severity of adverse events. The median final dose
was 250 mg (IQR, 200–300 mg).
Measurement of clinical parameters
All subjects were reviewed in terms of their clinical
characteristics, PFT results (including FVC and DLco),
arterial blood gas analysis, 6-min-walk test (6MWT),
and serum SP-A, SP-D, and KL-6 levels at baseline (at
the time of initiation of pirfenidone or nintedanib). The
6MWT was performed in accordance with the ATS
guidelines [16]. Serum levels of SP-A, SP-D, and KL-6
were measured by enzyme-linked immunosorbent assays
using commercial measurement kits as previously de-
scribed [15]. We assessed the correlation between the
parameters at baseline and those at 3 and 6months, and
the corresponding changes in FVC and DLco.
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Change in FVC and DLco, and definition of deterioration
Disease progression during pirfenidone and nintedanib
therapy was evaluated based on PFTs at 6 months (in-
cluding up to 9 months) from baseline [17]. “Progres-
sion” was defined as a ≥ 10% relative decline in FVC
from baseline and/or ≥ 15% relative decline in DLco
from baseline. Patients with progression were classified
into the “progression group,” whereas the others were
classified into the “stable group.”
Changes in SP-A, SP-D, and KL-6
The relative changes in serum SP-A, SP-D, and KL-6 at
3 months and 6months from baseline were evaluated.
Statistical analysis
All data are expressed as median (IQR). The Mann–
Whitney U test or Wilcoxon signed-rank test was used
to compare the differences between the stable group and
the progression group. To compare the levels of SP-A,
SP-D, and KL-6 at baseline, 3, and 6months in each
group, we performed the Friedman and Wilcoxon
signed-rank tests with Bonferroni correction, which are
non-parametric tests for comparing multiple groups of
the paired sample. Spearman’s rank correlation coeffi-
cient was used to evaluate the correlation between the
changes in serum biomarker levels and the change in
FVC and DLco. Logistic regression analysis was
performedto identify factors that predicted disease sta-
bility at 6 months from administration of anti-fibrotic
drugs. Factors associated with p-values < 0.20 in the uni-
variate analysis were included in the multivariate ana-
lysis. Receiver-operating characteristic (ROC) curves
were constructed for distinguishing between the stable
and progression for changes in serum SP-A, SP-D, and
KL-6. Cut-off levels were determined using the Youden
index. The use of these cut-off levels allowed the calcu-
lation of the sensitivity and specificity.
All tests were performed at a significance level of p <
0.05 or Bonferroni corrected p < 0.05. Statistical analysis
was performed using JMP 13.0 (SAS institute, Cary, NC,
USA).
Results
Study population, patient characteristics, and clinical data
Of the 93 patients with IPF who were initiated on pirfeni-
done or nintedanib therapy at our hospital, 49 patients
were included in this analysis (pirfenidone, 23; nintedanib,
26) (Fig. 1). Twenty patients were excluded because the
treatment was discontinued within 6months. Reasons for
discontinuation of pirfenidone treatment were disease
progression (n = 3), nausea (n = 2), loss of appetite, liver
function disorder, fever, xerophthalmia (n = 1, respect-
ively). Reasons for discontinuation of nintedanib treat-
ment were disease progression (n = 2), thrombocytopenia
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Fig. 1 Schematic illustration of the study design and patient-selection criteria
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(n = 2), nausea (n = 2), diarrhea, liver function disorder,
gastrointestinal bleeding, nasal bleeding, and rash (n = 1,
respectively). Thirteen patients were lost to follow-up and
were excluded. Eleven patients were excluded because
they were treated with corticosteroids and immunosup-
pressant drugs during the observation period.
Of the 49 patients included in this study, 32 patients
were classified as the “stable group” (pirfenidone, 17;
nintedanib, 15) and 17 patients were classified as the
“progression group” (pirfenidone, 6; nintedanib, 11). The
median observation period was 190.0 (169.8–263.2) days
in the stable group and 183.0 (171.5–189.5) days in the
progression group; there were no significant differences
between the stable and the progression groups. Baseline
characteristics were not significantly different between
the stable and the progression groups (Table 1). Of the
26 patients treated with nintedanib, seven patients had
past histories of treatment with pirfenidone (stable
group, 4; progression group, 3). Two patients developed
malignant tumor and were diagnosed with lung cancer.
No patients developed acute exacerbations during the
observation period. The changes in FVC and DLco from
baseline to 6 months are shown in Fig. 2. The median
change in FVC was 0.00 (− 0.08–0.09) L in the stable
group and − 0.16 (− 0.29 to − 0.11) L in the progression
group; the change in the stable group was significantly
smaller than that in the progression group (p < 0.01).
The median change in DLco was − 0.19 (− 1.00–0.42)
mL/min/mmHg in the stable group and − 2.08 (− 3.13 to
− 1.54) mL/min/mmHg in the progression group; the
change in the stable group was significantly smaller than
that in the progression group (p < 0.01).
Changes in serum biomarkers at 3 and 6months
The levels of SP-A, SP-D, and KL-6 at baseline, 3, and 6
months are shown in Table 2. In the stable group, SP-A
and KL-6 levels significantly decreased from baseline to
3 months and 6months. On the other hand, in the pro-
gression group, SP-A showed a significant increase from
baseline to 3 and 6months. KL-6 tended to increase at 3
and 6months; however, the difference was not signifi-
cant. At 6 months, KL-6 level in the stable group was
significantly lower than that in the progression group.
The relative changes in serum biomarker levels from
baseline to 3 and 6months are shown in Fig. 3. The
median change in SP-A at 3 and 6months was − 6.0
(− 20.1–3.6) % and − 10.2 (− 17.9 to − 3.85) % in the
stable group, and 16.7 (6.5–30.7) % and 20.2 (3.0–27.9)
% in the progression group; the changes at 3 and 6
months in the stable group were significantly smaller
than those in the progression group. The median change
in SP-D at 3 and 6months was − 10.6 (− 30.3–1.0) %
Table 1 Baseline characteristics and clinical data
Variable All subjects Stable group Progression group P-
value(n = 49) (n = 32) (n = 17)
Sex M/F (n) 38/11 24/8 14/3 0.56
Age (yr) 69 (65–75) 70 (66–76) 68 (64–75) 0.38
Smokers/never-smokers (n) 36/13 23/9 13/4 0.73
Pack-years smoking 30 (0.8–51.5) 34 (5–52.1) 25 (0.8–49.5) 0.61
BMI 23.8 (22.1–25.8) 23.6 (22.1–25.5) 25.0 (21.7–26.1) 0.43
GAP stage (n), I/II/III 20/24/5 14/15/3 6/9/2 0.84
FVC (L) 2.42 (2.08–2.86) 2.40 (2.09–3.65) 2.64 (2.02–2.78) 0.83
% FVC (%) 76.6 (65.4–92.5) 77.4 (65.1–94.4) 76.6 (66.4–86.9) 0.78
DLco (mL/min/mmHg) 10.7 (9.22–13.5) 10.6 (9.25–13.5) 10.7 (8.81–14.3) 0.76
% DLco (%) 52.8 (44.3–59.8) 52.8 (44.4–57.6) 51.7 (43.6–70.3) 0.97
PaO2 at rest (Torr) 82.7 (78.2–88.6) 81.5 (77.2–91.6) 83.8 (78.4–87.3) 0.71
Minimum SpO2 during 6MWT (%) 91 (87.3–93) 91 (88–93) 90 (85.5–93) 0.42
6MWT Distance (meter) 410 (380–480) 420 (385–480) 400 (360–490) 0.94
SP-A (ng/mL) 57.8 (41.7–79.1) 60.3 (42.6–76.1) 56.6 (40.6–96.7) 0.83
SP-D (ng/mL) 243 (181–352) 241 (177–357) 246 (166–350) 0.97
KL-6 (U/mL) 901 (663–1494) 885 (595.3–1618) 901 (732–1336) 0.44
pirfenidone/nintedanib 23/26 17/15 6/11 0.23
Treatment history of anti-fibrotic drug (n), yes/no 7/42 4/28 3/14 0.66
Data are expressed as frequencies or medians (interquartile range). P-value: stable group vs. progression group.
BMI body mass index; GAP (gender [G], age [A], and 2 lung physiology variables [P] [FVC and DLco]); FVC forced vital capacity; DLco diffusing capacity of the lung
for carbon monoxide; PaO2 partial pressure of arterial oxygen; SpO2 arterial oxygen saturation measured by pulse oximetry; 6MWT 6min-walk test; SP surfactant
protein; KL-6 Krebs von den Lungen-6
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and − 13.7 (− 32.1–2.2) % in the stable group and − 0.4
(− 18.6–35.8) % and 0.5 (− 6.0–24.7) % in the progres-
sion group; the changes at 6 months in the stable group
were significantly smaller than those in the progression
group. The median changes in KL-6 at 3 and 6months
were − 9.2 (− 22.5–4.1) % and − 15.0 (− 30.6−− 2.8) % in
the stable group and 6.7 (− 14.0–18.9) % and 12.1 (−
3.6–36.6) % in the progression group; the changes at 3
and 6months in the stable group were significantly
smaller than those in the progression group.
Pirfenidone and nintedanib subgroup evaluation
We performed subgroup analysis by disaggregating pa-
tients treated with pirfenidone and nintedanib. There
was no significant difference between pirfenidone group
and nintedanib group with respect to baseline character-
istics (See Additional file 5: Table S1).
In the pirfenidone group, serum SP-A in the stable
group was significantly lower than that in the progression
group (p < 0.05); however, no significant difference was
noted with respect to other baseline characteristics be-
tween the stable and progression subgroups of the pirfeni-
done and nintedanib groups. In both the pirfenidone and
nintedanib groups, the changes in FVC and DLco from
the baseline to 6months in the stable group were signifi-
cantly smaller than that in the progression group.
In patients treated with pirfenidone, the median
change in SP-A at 3 and 6months was − 6.0 (− 19.8–2.3)
% and − 10.3 (− 20.1 to − 5.9) % in the stable group and
28.6 (− 3.8–41.1) % and 25.1 (0–33.9) % in the progres-
sion group; the changes at 3 and 6months were signifi-
cantly smaller in the stable group than in the
progression group (p < 0.05) (See Additional file 1:
Figure S1). The median change in SP-D at 6 months was
− 12.7 (− 21.8–1.4) % in the stable group and 15.3
(− 5.8–26.7) % in the progression group; the change in
the stable group was significantly smaller than that in
the progression group (p < 0.05). The median change in
Fig. 2 Rate of change in (a) FVC and (b) DLco in the initial 6 months. Changes in FVC and DLco in the stable group were significantly smaller
than those in the progression group. Horizontal line indicates median concentration. The upper and lower limits of the line indicate the inter
quartile range. Data were analyzed by Mann–Whitney U test. *p < 0.01 stable vs. progression group. FVC, forced vital capacity; DLco, diffusing
capacity of the lung for carbon monoxide
Table 2 Serum levels of SP-A, SP-D, and KL-6 at baseline, 3, and 6 months
Baseline 3 months 6 months
Stable group
SP-A (ng/mL) 60.3 (42.6–76.1) 53.1 (36.6–68.0) * 49.2 (37.1–71.7) *
SP-D (ng/mL) 241 (177–357) 194 (149–296) 195 (128–263)
KL-6 (U/mL) 885 (595–1618) 775 (581–1154) * 738 (503–1213) *#
Progression group
SP-A (ng/mL) 56.6 (40.6–96.7) 67.0 (46.8–111.8) * 69.3 (42.7–117.8) *
SP-D (ng/mL) 246 (166–350) 261 (180–323) 224 (192–353)
KL-6 (U/mL) 901 (732–1337) 1195 (653–1821) 1237 (748–1570) #
Data are expressed as medians (interquartile range).
*: Bonferroni-corrected p < 0.05 baseline vs. 3 or 6 months. #: p < 0.05 stable group vs. progression group. SP surfactant protein; KL-6 Krebs von den Lungen-6
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KL-6 at 3 and 6months was − 8.6 (− 16.9–7.4) % and −
8.5 (− 32.2–0.8) % in the stable group and 14.3 (− 0.5–
86.1) % and 25.5 (7.5–44.3) % in the progression group;
the changes at 3 and 6months in the stable group were
significantly smaller than those in the progression group
(p < 0.05). In patients treated with nintedanib, the me-
dian change in SP-A at 3 and 6months was − 5.0
(− 23.0–4.5) % and − 10.0 (− 18.5–5.6) % in the stable
group and 14.7 (8.7–21.0) % and 18.7 (1.9–25.8) % in
the progression group; the changes at 3 and 6months in
the stable group were significantly smaller than those in
the progression group (p < 0.05). The median change in
KL-6 at 6 months was − 16.6 (− 24.7 to − 4.7) % in the
stable group and 6.8 (− 6.8–16.9) % in the progression
group; the change was significantly smaller in the stable
group than in the progression group (p < 0.05). The
changes in SP-D were not significantly different between
these groups.
Correlation between serum biomarkers and PFTs
The correlation between the changes in serum bio-
marker levels and the change in FVC and DLco are
shown in Fig. 4. We observed a negative correlation be-
tween the change in FVC at 6 months and the changes
in SP-A (correlation coefficient: − 0.46, p < 0.01) and SP-
D (correlation coefficient: − 0.39, p < 0.01) at 6 months.
We also observed a negative correlation between the
change in DLco and the changes in SP-A (correlation
coefficient: − 0.67, p < 0.01), SP-D (correlation coeffi-
cient: − 0.54, p < 0.01) and KL-6 (correlation coefficient:
− 0.47, p < 0.01).
In patients treated with pirfenidone, we observed a
negative correlation between the change in FVC at 6
months and change in SP-A (correlation coefficient: −
0.60, p < 0.01) and SP-D (correlation coefficient: − 0.49,
p < 0.05) at 6 months; similarly, we observed a negative
correlation between the change in DLco and changes in
SP-A (correlation coefficient: − 0.59, p < 0.05), SP-D
(correlation coefficient: − 0.56, p < 0.05), and KL-6 (cor-
relation coefficient: − 0.48, p < 0.05) (See Additional file
6: Table S2). In patients treated with nintedanib, we ob-
served a negative correlation between the change in
DLco and changes in SP-A (correlation coefficient: −
0.61, p < 0.01), SP-D (correlation coefficient: − 0.42, p <
0.05), and KL-6 (correlation coefficient: − 0.47, p < 0.05).
Predictive factors of therapeutic effect of anti-fibrotic
drugs
We performed logistic regression analysis to identify fac-
tors that predicted therapeutic outcome at 6 months
(Table 3). On univariate analysis, the change in SP-A at
3 months (odd’s ratio [OR] 0.89, 95% CI 0.82–0.96, p <
0.01), KL-6 at 3 months (OR 0.96, 95% CI 0.92–0.99, p <
0.01), SP-A in 6 months (OR 0.89, 95% CI 0.84–0.95,
p < 0.01), SP-D in 6 months (OR 0.95, 95% CI 0.92–0.99,
p < 0.01), and KL-6 in 6months (OR 0.93, 95% CI 0.89–
0.97, p < 0.01) showed a significant association with out-
comes. Three multivariate analysis models were con-
structed (Table 4). When the change in SP-A, SP-D, and
KL-6 at 3 months were entered in the 3 months model
(model 1), the change in SP-A at 3 months was a signifi-
cant predictive factor (OR 0.88, 95% CI 0.80–0.97, p <
0.01). When the change in SP-A, SP-D, and KL-6 at 6
months were entered in the 6 months model (model 2),
the change in SP-A at 6 months was a significant pre-
dictive factor (OR 0.90, 95% CI 0.84–0.97, p < 0.01). In
the 3 months model and 6months model (model 3), the
changes in SP-A at 3 and 6months were significant pre-
dictive factors (OR 0.89, 95% CI 0.76–0.98, p < 0.05; OR
0.88, 95% CI 0.76–0.96, p < 0.01; respectively).
We analyzed the sensitivity and specificity to distin-
guish between the stable and the progressive patients for
Fig. 3 Relative change in (a) SP-A, (b) SP-D, and (c) KL-6 levels in the initial 3 and 6months. Changes in serum SP-A at 3 and 6months, SP-D at 6
months, and KL-6 at 3 and 6months were significantly smaller in the stable group than the progression group (*p < 0.05). Data were analyzed by
Mann–Whitney U test. Horizontal line indicates median concentration. The upper and lower limits of the box indicate the inter quartile range
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changes in SP-A, SP-D, and KL-6. The sensitivity and
specificity estimated according to the ROC curve ana-
lyses are shown in Table S3 (See Additional file 7). The
sensitivity, specificity and the AUC of change in SP-A in
3 months were 93, 75%, and 0.89, respectively. The sen-
sitivity, specificity and AUC of change in SP-A in 6
months were 81, 81%, and 0.89, respectively.
Discussion
We report an association between changes in serum SP-
A, SP-D, and KL-6 levels and change in FVC and DLco
of patients with IPF treated with anti-fibrotic drugs. Pa-
tients with IPF who maintained their FVC and DLco
showed a significant decrease in SP-A and KL-6 at 3 and
6months. On the other hand, those who showed decline
in FVC and DLco had increased SP-A levels at 3 and 6
months. The relative changes in serum biomarkers were
significantly smaller in the stable group than in the pro-
gression group. The changes in serum biomarker levels
showed a significant correlation with changes in FVC
and DLco. In particular, changes in SP-A levels most
closely reflected the outcomes of anti-fibrotic therapy.
This study indicates that SP-A may be used as a bio-
marker to predict the outcomes of anti-fibrotic drug
therapy.
Serum levels of SP-A, SP-D, and KL-6 have been shown
to be useful in predicting prognosis and monitoring dis-
ease activity in patients with IPF [12, 18, 19]. In previous
studies, SP-A was found to be a predictor of early mortal-
ity in patients with IPF [19, 20]. In our previous studies,
patients with high levels of SP-D tended to exhibit wors-
ening restrictive impairment and poor prognosis [13, 21].
Serum KL-6 levels were shown to correlate with the sever-
ity and prognosis of patients with IPF [14, 22]; in addition,
serial change in KL-6 levels was a prognostic factor for pa-
tients with IPF [23, 24]. However, the usefulness of these
serum biomarkers in patients undergoing anti-fibrotic
drug therapy is not well characterized. A few studies have
investigated the clinical relevance of SP-D and KL-6 levels
in the context of pirfenidone therapy. For example, SP-D
was shown to be prognostic marker in patients with IPF
treated with pirfenidone [15]. Similarly, in a study by
Okuda, et al., levels of KL-6 and SP-D were decreased by
pirfenidone therapy [25]. The present study showed that
changes in serum biomarkers may serve as useful markers
for clinical evaluation and monitoring of therapeutic effi-
cacy in patients with IPF treated with anti-fibrotic drugs.
Thus, our study provides novel insights for further investi-
gations to verify the clinical relevance of these serum bio-
markers in the context of anti-fibrotic therapy for IPF.
Fig. 4 Correlation between changes in (a) FVC and (b) DLco and changes in SP-A, SP-D, and KL-6. (a) Decline in FVC showed a correlation with
decrease in serum SP-A and SP-D (r = − 0.46 and r = − 0.39, respectively, p < 0.01). (b) Decline in DLco showed a correlation with decrease in
serum SP-A, SP-D, and KL-6 (r = − 0.67, r = − 0.54, and r = − 0.47 respectively, p < 0.01). Spearman’s correlation coefficients were used to analyze
the linear relationship between the variables
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In the present study, serum biomarker levels at base-
line did not show any significant differences between the
stable group and the progression group. In our previous
study, baseline level of SP-D was found to predict mor-
tality of patients with IPF treated with pirfenidone [15].
This discrepancy may be partly explained by the shorter
duration of follow-up and the difference in the definition
of deterioration (including not only FVC but also
DLCO) in the present study. In addition, previous study
lacked longitudinal assessment to determine whether
changes in serum biomarker levels reflect the thera-
peutic effect. In a study by Sokai, et al., serial changes in
KL-6 in patients with IPF showed a significant correl-
ation with changes in FVC and DLco; in addition, serial
change in KL-6 level was a predictor of mortality; how-
ever, most of patients were not treated with anti-fibrotic
drugs [24]. Our study is the first to demonstrate that
serial changes in SP-A and KL-6 reflect the decline in
pulmonary function of patients with IPF treated with
anti-fibrotic drugs. These results suggest that serial
measurement of serum biomarker levels is more useful
for monitoring patients with IPF and their response to
anti-fibrotic therapy.
IPF is a progressive lung disease characterized by de-
cline in FVC. In both ASCEND and INPULSIS-1/2
phase III trials, the primary endpoint was the annual rate
of decline in FVC [4, 5]. Currently, alleviation of the rate
of decline in FVC is the only criterion to ascertain the
therapeutic efficacy of pirfenidone and nintedanib. No
other biomarker of the therapeutic effect of anti-fibrotic
therapy has been elucidated. It is difficult to evaluate the
degree of efficacy of pirfenidone and nintedanib by pul-
monary function tests alone. Furthermore, it is difficult
to perform pulmonary function tests frequently in pa-
tients with severe IPF owing to the following reasons: 1)
it imposes a physical burden on patients with serious
disease; 2) the results depend on the patient’s efforts; 3)
maximal effort may be difficult because of cough; 4)
DLco cannot be measured in severe cases. Therefore,
use of pulmonary function tests in conjunction with
serum biomarkers will help reduce the burden on pa-
tients and allow for more frequent assessments. More-
over, this will facilitate more accurate assessment of the
therapeutic outcomes of pirfenidone and nintedanib.
In IPF, serial changes in FVC and DLco at 6 or 12
months show greater prognostic value than baseline data
[26, 27]. Even a decline in FVC by 5–10% at 6 months
was associated with increased mortality [27]. In the
study by Du Bois et al., change in percent-predicted
FVC over 6 months was a strong predictor of death over
1-year period [28]. Risk of death was nearly five-fold
higher for patients with > 10% decline in percent-
Table 4 Prediction of stability at 6 months from administration of anti-fibrotic drugs in multivariate analysis
variable model 1 model 2 model 3 (model 1 + model 2)
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Change in SP-A in 3 months (%) 0.88 (0.80–0.97) < 0.01 – – 0.89 (0.76–0.98) < 0.05
Change in SP-D in 3 months (%) 1.10 (0.98–1.05) 0.28 – – 1.04 (0.99–1.13) 0.09
Change in KL-6 in 3 months (%) 0.99 (0.95–1.03) 0.67 – – 0.99 (0.92–1.04) 0.71
Change in SP-A in 6 months (%) – – 0.90 (0.84–0.97) < 0.01 0.88 (0.76–0.96) < 0.01
Change in SP-D in 6 months (%) – – 0.98 (0.92–1.03) 0.37 0.98 (0.90–1.04) 0.49
Change in KL-6 in 6 months (%) – – 0.95 (0.90–1.01) 0.05 0.96 (0.87–1.03) 0.30
OR odd’s ratio; SP surfactant protein; KL-6 Krebs von den Lungen-6
Table 3 Prediction of stability at 6 months from administration
of anti-fibrotic drugs in univariate analysis
Variable OR (95% CI) P-value
Sex, Male 0.64 (0.15–2.83) 0.55
Age 1.05 (0.96–1.14) 0.24
Smokers 1.27 (0.33–4.96) 0.72
Pack-years smoking 1.01 (0.99–1.03) 0.59
BMI 0.89 (0.74–1.08) 0.22
% FVC (%) 1.01 (0.98–1.04) 0.61
% DLco (%) 1.00 (0.95–1.04) 0.83
PaO2 at rest (Torr) 1.01 (0.94–1.09) 0.71
Minimum SpO2 during 6MWT (%) 1.06 (0.93–1.21) 0.37
6MWT Distance (m) 1.00 (0.99–1.01) 0.80
SP-A (ng/mL) 0.99 (0.98–1.01) 0.30
SP-D (ng/mL) 1.00 (1.00–1.00) 0.64
KL-6 (U/mL) 1.00 (1.00–1.00) 0.65
Pirfenidone 2.01 (0.62–6.99) 0.23
Treatment history of anti-fibrotic drugs (n) 0.69 (0.14–3.53) 0.66
Change in SP-A in 3 months (%) 0.89 (0.82–0.96) < 0.01
Change in SP-D in 3 months (%) 0.98 (0.96–1.00) 0.12
Change in KL-6 in 3 months (%) 0.96 (0.92–0.99) < 0.01
Change in SP-A in 6 months (%) 0.89 (0.84–0.95) < 0.01
Change in SP-D in 6 months (%) 0.95 (0.92–0.99) < 0.01
Change in KL-6 in 6 months (%) 0.93 (0.89–0.97) < 0.01
OR odd’s ratio; BMI body mass index; FVC forced vital capacity; DLco diffusing
capacity of the lung for carbon monoxide; PaO2 partial pressure of arterial
oxygen; SpO2 arterial oxygen saturation measured by pulse oximetry; 6MWT 6
min-walk test; SP surfactant protein; KL-6 Krebs von den Lungen-6
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predicted FVC, and two-fold higher for those with 5–
10% decline [28]. The rate of decline in FVC at 6 months
is associated with the subsequent prognosis. Although
the evaluation period in this study was 6 months, it was
considered to be an appropriate period for prognostic
assessment. Furthermore, absence of signs of therapeutic
effect at 6 months should prompt reconsideration of
treatment such as a change to another anti-fibrotic drug.
Patients with IPF show increased production of SP-
A, SP-D, and KL-6 by alveolar type 2 epithelial cells
in the lung tissues [11, 12, 29]. Levels of SP-A and
SP-D in bronchoalveolar lavage (BAL) fluid in pa-
tients with IPF were shown to decrease as compared
to healthy subjects, whereas levels of KL-6 were
shown to increase [29–31]. It is considered that
serum SP-A, SP-D, and KL-6 levels are elevated due
to increased vascular leakage from the alveolar space,
probably due to epithelial detachment, basement
membrane injury, and capillary fragility [15, 29]. In
this study, serum SP-A and KL-6 levels were found to
decrease after treatment with anti-fibrotic drugs.
These results may be explained by the following
mechanisms of action of nintedanib: 1) suppression of
vascular permeability and capillary angiogenesis via
VEGF; 2) repair of lung tissue with reduction of
fibroblast migration and cell proliferation with PDGF
and FGF; 3) suppression of the production of SP-A in
alveolar type 2 epithelial cells by FGF. Pirfenidone
suppresses the production of TGF-β and inflamma-
tory cytokines in addition to PDGF and FGF [32, 33].
It may also reduce the leakage by suppressing the
production of SP-A and KL-6 by epithelial cells and
by reducing abnormal tissue repair.
In the present study, in both pirfenidone and ninteda-
nib groups, there was no difference in the reduction rate
of pulmonary function between the stable group and the
progression group; in addition, the number of patients
in the stable group was also similar. Although the differ-
ence between the therapeutic effect of pirfenidone and
nintedanib has not been clarified, the therapeutic effects
may be comparable [34]. Moreover, it is not clear
whether change from one anti-fibrotic drug to the other
accrues any additional benefit. In the present study
population, seven patients with IPF were shifted from
pirfenidone to nintedanib; however, there was no differ-
ence between the stable and progression groups with re-
spect to history of treatment with pirfenidone. Our
results also showed additional therapeutic benefit in
these patients, although the number of patients was
small. A previous report also documented the thera-
peutic benefit of change in anti-fibrotic drug in a small
number of cases; this phenomenon may be attributable
to the different mechanisms of action of these drugs
[35]. Further studies with larger sample are required to
obtain more definitive evidence of the benefit of treat-
ment with two anti-fibrotic drugs, and to determine the
optimal sequence of use of anti-fibrotic drugs.
The present study has some limitations. First, this was
a single-center retrospective study with a small sample
size. Further, the number of subjects has decreased
because 11 patients, including 3 cases where patients
developed acute exacerbation before anti-fibrotic drug
administration, were excluded because corticosteroid
therapy was considered to affect serum biomarker ex-
pression. In the present study, we evaluated 60 people,
including 11 patients who received treatment with corti-
costeroids and confirmed that the results were the same
(see Additional files 2,3,4,8,9,10,11: Figure S2–S4, Table
S4–S7). Therefore, treatment with steroids does not
affect the results, and we thus believe that sampling er-
rors will not occur in this study that has continued for
more than 6months. Second, nintedanib has been avail-
able in Japan since August 2015; therefore, only pirfeni-
done was available for use during the initial period of
the study reference period. The nintedanib group in-
cluded some patients who had a history of treatment
with pirfenidone. However, there were no significant dif-
ferences between the pirfenidone and nintedanib groups
with respect to baseline characteristics, clinical data, and
outcomes. Third, this study did not include a group that
was not treated with anti-fibrotic drugs; thus, it may not
be concluded that the amelioration of decline in FVC
and DLco was attributable to anti-fibrotic drug therapy.
However, it is difficult to plan comparative studies on
the treatment of IPF in an era when anti-fibrotic drugs
have become the standard therapy for treating IPF. Fi-
nally, the observation period was 6 months, and long-
term efficacy and prognosis have not been investigated.
It is necessary to clarify the relationship of serum bio-
markers with therapeutic effect and prognosis over a
longer term.
Conclusion
Changes in serum SP-A levels reflected the outcomes of
anti-fibrotic drug therapy. Serial measurements of SP-A
may serve as a useful therapeutic biomarker and may
help guide the management of IPF.
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Additional file 1: Figure S1. Relative change in SP-A, SP-D, and KL-6 in
patients treated with (A) pirfenidone and (B) nintedanib. (A) Change in
SP-A at 3 and 6 months, SP-D at 6 months, and KL-6 at 3 and 6months
were significantly smaller in the stable group than the progression group
(p < 0.05). (B) Change in SP-A at 3 and 6 months and KL-6 at 6 months
were significantly smaller in the stable group than the progression group
(p < 0.05)
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Additional file 2: Figure S2. Rate of change in (A) FVC and (B) DLco in
the initial 6 months of population which included patients who used
corticosteroids. Changes in FVC and DLco in the stable group were
significantly smaller than those in the progression group (p < 0.01)
Additional file 3: Figure S3. Relative change in (A) SP-A, (B) SP-D, and
(C) KL-6 levels in the initial 3 and 6 months of population which included
patients who used corticosteroids. Changes in SP-A, SP-D, and KL-6 at 3
and 6months were significantly smaller in the stable group than the pro-
gression group (p < 0.05)
Additional file 4: Figure S4. Correlation between changes in (A) FVC
and (B) DLco and changes in SP-A, SP-D, and KL-6 of population which
included patients who used corticosteroids. (A) Change in FVC showed a
negative correlation with changes in SP-A and SP-D (p < 0.01). (B) Change
in DLco showed a negative correlation with changes in SP-A, SP-D, and
KL-6 (p < 0.01)
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